[
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "CV",
    "section": "",
    "text": "Download full CV (PDF)"
  },
  {
    "objectID": "cv.html#education",
    "href": "cv.html#education",
    "title": "CV",
    "section": "Education",
    "text": "Education\nBA, Religious Studies - Brown University\nMD - Warren Alpert School of Medicine, Brown University"
  },
  {
    "objectID": "cv.html#training",
    "href": "cv.html#training",
    "title": "CV",
    "section": "Training",
    "text": "Training\nPsychiatry Resident - Johns Hopkins Hospital\nPostdoctoral Fellow - Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine (2020–2022)"
  },
  {
    "objectID": "cv.html#current-appointments",
    "href": "cv.html#current-appointments",
    "title": "CV",
    "section": "Current Appointments",
    "text": "Current Appointments\nAssistant Professor - Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine (2022–present)\nMedical Director - Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine (2023–present)"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Sandeep M. Nayak, MD",
    "section": "",
    "text": "Sandeep M. Nayak, MD, is an Assistant Professor of Psychiatry at Johns Hopkins and Medical Director of the Center for Psychedelic & Consciousness Research. He joined the center in 2020, completed a postdoctoral fellowship with Roland Griffiths, PhD, and then transitioned to faculty.\nSandeep is currently Principal Investigator of three clinical trials: - BIPOD: a randomized trial of psilocybin for Opioid Use Disorder alongside buprenorphine - Pilot study of psilocybin for PTSD - Microdose psilocybin safety study\nHis interests clinical applications of psychedelics, Bayesian statistics, clinical-trial methodology, belief change, and psychedelic anthropology. He is also a practicing psychiatrist."
  },
  {
    "objectID": "index.html#contact",
    "href": "index.html#contact",
    "title": "Sandeep M. Nayak, MD",
    "section": "Contact",
    "text": "Contact\n\nEmail: smn@jhmi.edu\nGoogle Scholar · ORCID · GitHub\nTwitter/X · Hopkins Profile\n\nCurrent projects. BIPOD (psilocybin for OUD), microdosing safety, PTSD trial design, preparation/integration methods."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "Nayak, S.M. & Zahid, Z. (2025). Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials. Journal of Psychopharmacology. [pdf]\nNayak, S.M., White, S.H., Hilbert, S.N., Lowe, M.X., Jackson, H., Griffiths, R.R., Garcia-Romeu, A., & Yaden, D.B. (2025). Psychedelic experiences increase mind perception but do not change atheist-believer status: A prospective longitudinal study. Journal of Psychoactive Drugs, 57(3), 275–284. [pdf]\nRichard, J., Scott, J., Nayak, S.M., Sepeda, N.D., Lowe, M.X., Jackson, H., & Garcia-Romeu, A. (2025). Patterns of internalizing problems, substance use and cognitive flexibility before and after naturalistic psilocybin use: A repeated measures latent profile analysis. International Journal of Mental Health and Addiction.\nRichard, J., Nayak, S.M., Sepeda, N., & Garcia-Romeu, A. (2025). Latent class analysis of changes in substance use and depressive symptoms following naturalistic psilocybin use: Results from a prospective longitudinal survey. Drug and Alcohol Dependence, 267, 112184.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). Psychological support approaches in psychedelic therapy: Results from a survey of psychedelic practitioners. The Journal of Clinical Psychiatry, 86(1), 24m15521.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). The role of touch in psychedelic therapy: Perspectives from a survey of practitioners in research settings. American Journal of Psychotherapy.\nGoldy, S.P., Du, B.A., Rohde, J.S., Nayak, S.M., Strickland, J.C., Ehrenkranz, R., Levine, M., Barrett, F.S., & Yaden, D.B. (2025). Psychedelic risks and benefits: A cross-sectional survey study. Journal of Psychopharmacology, 39(5), 436–452.\nSingleton, S.P., Sevchik, B.L., Vandekar, S.N., Strain, E.C., Nayak, S.M., Dworkin, R.H., Scott, J.C., & Satterthwaite, T.D. (2025). An initiative for living evidence synthesis in clinical psychedelic research. Nature Mental Health, 3(1), 3–5.\nYaden, D.B., Graziosi, M., Owen, A.M., Agin-Liebes, G., Aaronson, S.T., Allen, K.E., Barrett, F.S., Bogenschutz, M.P., Carhart-Harris, R., Ching, T.H.W., Nayak, S.M., & Yaden, M.E. (2025). A field-wide review and analysis of study materials used in psilocybin trials: Assessment of two decades of research. Psychedelic Medicine, 3(1), 1–18.\nMathai, D.S., Roberts, D.E., Nayak, S.M., Sepeda, N.D., Lehrner, A., Johnson, M.W., Lowe, M.X., Jackson, H., & Garcia-Romeu, A. (2025). Shame, guilt, and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. Journal of Psychoactive Drugs.\nEhrenkranz, R., Agrawal, M., Nayak, S.M., & Yaden, D.B. (2025). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine, 3(1), 59–62.\nBarnett, B.S., Vest, M.F., Delatte, M.S., King IV, F., Mauney, E.E., Coulson, A.J., Nayak, S.M., Hendricks, P.S., Greer, G.R., & Murnane, K.S. (2025). Practical considerations in the establishment of psychedelic research programs. Psychopharmacology, 242(1), 27–43.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). Psychedelic therapies: One drug, multiple treatments reply to Modesto-Lowe et al. The Journal of Clinical Psychiatry, 86(4), 25lr15978a.\nJones, G., Lowe, M.X., Nayak, S., Sepeda, N., Kettner, H., Carhart-Harris, R., Jackson, H., & Garcia-Romeu, A. (2025). Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. participants of Color: A longitudinal online survey study. Journal of Affective Disorders, 370, 54–61."
  },
  {
    "objectID": "publications.html#section",
    "href": "publications.html#section",
    "title": "Publications",
    "section": "",
    "text": "Nayak, S.M. & Zahid, Z. (2025). Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials. Journal of Psychopharmacology. [pdf]\nNayak, S.M., White, S.H., Hilbert, S.N., Lowe, M.X., Jackson, H., Griffiths, R.R., Garcia-Romeu, A., & Yaden, D.B. (2025). Psychedelic experiences increase mind perception but do not change atheist-believer status: A prospective longitudinal study. Journal of Psychoactive Drugs, 57(3), 275–284. [pdf]\nRichard, J., Scott, J., Nayak, S.M., Sepeda, N.D., Lowe, M.X., Jackson, H., & Garcia-Romeu, A. (2025). Patterns of internalizing problems, substance use and cognitive flexibility before and after naturalistic psilocybin use: A repeated measures latent profile analysis. International Journal of Mental Health and Addiction.\nRichard, J., Nayak, S.M., Sepeda, N., & Garcia-Romeu, A. (2025). Latent class analysis of changes in substance use and depressive symptoms following naturalistic psilocybin use: Results from a prospective longitudinal survey. Drug and Alcohol Dependence, 267, 112184.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). Psychological support approaches in psychedelic therapy: Results from a survey of psychedelic practitioners. The Journal of Clinical Psychiatry, 86(1), 24m15521.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). The role of touch in psychedelic therapy: Perspectives from a survey of practitioners in research settings. American Journal of Psychotherapy.\nGoldy, S.P., Du, B.A., Rohde, J.S., Nayak, S.M., Strickland, J.C., Ehrenkranz, R., Levine, M., Barrett, F.S., & Yaden, D.B. (2025). Psychedelic risks and benefits: A cross-sectional survey study. Journal of Psychopharmacology, 39(5), 436–452.\nSingleton, S.P., Sevchik, B.L., Vandekar, S.N., Strain, E.C., Nayak, S.M., Dworkin, R.H., Scott, J.C., & Satterthwaite, T.D. (2025). An initiative for living evidence synthesis in clinical psychedelic research. Nature Mental Health, 3(1), 3–5.\nYaden, D.B., Graziosi, M., Owen, A.M., Agin-Liebes, G., Aaronson, S.T., Allen, K.E., Barrett, F.S., Bogenschutz, M.P., Carhart-Harris, R., Ching, T.H.W., Nayak, S.M., & Yaden, M.E. (2025). A field-wide review and analysis of study materials used in psilocybin trials: Assessment of two decades of research. Psychedelic Medicine, 3(1), 1–18.\nMathai, D.S., Roberts, D.E., Nayak, S.M., Sepeda, N.D., Lehrner, A., Johnson, M.W., Lowe, M.X., Jackson, H., & Garcia-Romeu, A. (2025). Shame, guilt, and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. Journal of Psychoactive Drugs.\nEhrenkranz, R., Agrawal, M., Nayak, S.M., & Yaden, D.B. (2025). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine, 3(1), 59–62.\nBarnett, B.S., Vest, M.F., Delatte, M.S., King IV, F., Mauney, E.E., Coulson, A.J., Nayak, S.M., Hendricks, P.S., Greer, G.R., & Murnane, K.S. (2025). Practical considerations in the establishment of psychedelic research programs. Psychopharmacology, 242(1), 27–43.\nBender, D.A., Nayak, S.M., Siegel, J.S., Hellerstein, D.J., Ercal, B.C., & Lenze, E.J. (2025). Psychedelic therapies: One drug, multiple treatments reply to Modesto-Lowe et al. The Journal of Clinical Psychiatry, 86(4), 25lr15978a.\nJones, G., Lowe, M.X., Nayak, S., Sepeda, N., Kettner, H., Carhart-Harris, R., Jackson, H., & Garcia-Romeu, A. (2025). Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. participants of Color: A longitudinal online survey study. Journal of Affective Disorders, 370, 54–61."
  },
  {
    "objectID": "publications.html#section-1",
    "href": "publications.html#section-1",
    "title": "Publications",
    "section": "2024",
    "text": "2024\nHinkle, J.T., Graziosi, M., Nayak, S.M., & Yaden, D.B. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. JAMA Psychiatry. [pdf]\nYaden, D.B., Gukasyan, N., Nayak, S.M. (2024). Psilocybin in bipolar II study provides preliminary data on safety. JAMA Psychiatry, 81(6), 541–542.\nNayak, S.M. & Johnson, M.W. (2024). Disorders due to substance use: Hallucinogens and MDMA-related substances. In Tasman’s Psychiatry (5th ed., pp. 2653–2686). Springer International Publishing. [pdf]\nBarnett, B.S., Anand, A., Dewey, E.N., Smith, D., Nayak, S.M., Bruckman, D., & Weleff, J. (2024). Perceived risk of trying lysergic acid diethylamide in the United States from 2015 to 2019: Are Americans assessing lysergic acid diethylamide’s risk profile more favorably? Psychedelic Medicine, 2(2), 74–86.\nDavis, A.K., Timmermann, C., Ortiz Bernal, A.M., Lancelotta, R., Nayak, S.M., Sepeda, N.D., Nikolaidis, A., & Griffiths, R.R. (2024). Translation and initial psychometric evaluation of Spanish versions of three psychedelic acute effects measures: Mystical, challenging, and insight experiences. Journal of Psychoactive Drugs, 56(4), 456–466.\nLevin, A.W., Lancelotta, R., Sepeda, N.D., Gukasyan, N., Nayak, S.M., Wagener, T.L., Barrett, F.S., Griffiths, R.R., & Davis, A.K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLOS ONE, 19(3), e0300501.\nWang, E., Mathai, D.S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Scientific Reports, 14(1), 28022.\nMeling, D., Ehrenkranz, R., Nayak, S.M., Aicher, H.D., Funk, X., van Elk, M., Graziosi, M., Bauer, P.R., Scheidegger, M., & Yaden, D.B. (2024). Mind the psychedelic hype: Characterizing the risks and benefits of psychedelics for depression. Psychoactives, 3(2), 215–234.\nGordon, A.R., Carrithers, B.M., Pagni, B.A., Kettner, H., Marrocu, A., Nayak, S., Weiss, B.J., Carhart-Harris, R.L., Roberts, D.E., Erritzoe, D. (2024). The effect of psychedelics on individuals with a personality disorder: Results from two prospective cohort studies.\nJacobs, E., Earp, B.D., Appelbaum, P.S., Bruce, L., Cassidy, K., Celidwen, Y., Cheung, K., Clancy, S.K., Devenot, N., Evans, J., Nayak, S.M., Yaden, D.B. (2024). The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group consensus statement. The American Journal of Bioethics, 24(7), 6–12.\nO’Donnell, K.C., Anderson, B.T., Barrett, F.S., Bogenschutz, M.P., Grob, C.S., Hendricks, P.S., Kelmendi, B., Nayak, S.M., Nicholas, C.R., Paleos, C.A. (2024). Misinterpretations and omissions: A critical response to Goodwin and colleagues’ commentary on psilocybin-assisted therapy. American Journal of Psychiatry, 181(1), 74–75.\nDworkin, R.H., McDermott, M.P., Nayak, S.M., Strain, E.C. (2024). Reply to “Capturing synergy holistically in psychedelic clinical trials.” Clinical Pharmacology & Therapeutics, 115(3).\nYaden, D.B., Nayak, S.M., Griffiths, R.R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In C. Letheby & P. Gerrans (Eds.), Philosophical Perspectives on Psychedelic Psychiatry. Oxford Academic.\nDavis, A., Levin, A., Lancelotta, R., Sepeda, N., Gukasyan, N., Nayak, S., Barrett, F., Griffiths, R. (2024). Acute psychedelic effects and clinical outcomes are associated with therapeutic alliance among participants receiving psilocybin therapy. Drug and Alcohol Dependence, 260, 110609.\nLancelotta, R., Timmerman, C., Bernal, A.M.O., Nayak, S., Sepeda, N.D., Nikolaidis, A., Griffiths, R.R., Davis, A.K. (2024). Associations between harm reduction strategy use and acute psychedelic effects in Spanish speakers who used LSD or psilocybin. Drug and Alcohol Dependence, 260, 110861.\nYaden, D.B., Berghella, A.P., Hendricks, P.S., Yaden, M.E., Levine, M., Rohde, J.S., Nayak, S., Johnson, M.W., Garcia-Romeu, A. (2024). IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research, 199, 106998."
  },
  {
    "objectID": "publications.html#section-2",
    "href": "publications.html#section-2",
    "title": "Publications",
    "section": "2023",
    "text": "2023\nNayak, S.M., Singh, M., Yaden, D.B., & Griffiths, R.R. (2023). Belief changes associated with psychedelic use. Journal of Psychopharmacology, 37(1), 80–92. [pdf]\nNayak, S.M., Bari, B.A., Yaden, D.B., Spriggs, M.J., Rosas, F.E., Peill, J.M., Giribaldi, B., Erritzoe, D., Nutt, D.J., & Carhart-Harris, R. (2023). A Bayesian reanalysis of a trial of psilocybin versus escitalopram for depression. Psychedelic Medicine, 1(1), 18–26. [pdf]\nNayak, S.M., Bradley, M.K., Kleykamp, B.A., Strain, E.C., Dworkin, R.H., & Johnson, M.W. (2023). Control conditions in randomized trials of psychedelics: An ACTTION systematic review. The Journal of Clinical Psychiatry, 84(3), 22r14518. [pdf]\nGukasyan, N., Griffiths, R.R., Yaden, D.B., Antoine, D.G., Nayak, S.M. (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 37(7), 707–716. [pdf]\nNayak, S.M., Jackson, H., Sepeda, N.D., Mathai, D.S., So, S., Yaffe, A., Zaki, H., Brasher, T.J., Lowe, M.X., Jolly, D.R.P., & Garcia-Romeu, A. (2023). Naturalistic psilocybin use is associated with persisting improvements in mental health and well-being: Results from a prospective, longitudinal survey. Frontiers in Psychiatry, 14, 1199642.\nMathai, D.S., Nayak, S.M., Yaden, D.B., & Garcia-Romeu, A. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology, 240(4), 827–836.\nRaison, C.L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B.W., Brown, R.T., Kakar, R., Hassman, M., Trivedi, R.P., Robison, R., Nayak, S.M., & Griffiths, R.R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA, 330(9), 843–853.\nGraziosi, M., Singh, M., Nayak, S.M., Yaden, D.B. (2023). Acute subjective effects of psychedelics within and beyond WEIRD contexts. Journal of Psychoactive Drugs, 55(5), 558–569.\nDworkin, R.H., McDermott, M.P., Nayak, S.M., Strain, E.C. (2023). Psychedelics and psychotherapy: Is the whole greater than the sum of its parts? Clinical Pharmacology & Therapeutics, 114(6), 1166–1169."
  },
  {
    "objectID": "publications.html#section-3",
    "href": "publications.html#section-3",
    "title": "Publications",
    "section": "2022",
    "text": "2022\nGukasyan, N. & Nayak, S.M. (2022). Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcultural Psychiatry, 59(5), 652–664.\nHuhn, A.S., Strain, E.C., Jardot, J., Turner, G., Bergeria, C.L., Nayak, S.M., & Dunn, K.E. (2022). Treatment disruption and childcare responsibility as risk factors for drug and alcohol use in persons in treatment for substance use disorders during the COVID-19 crisis. Journal of Addiction Medicine, 16(1), e8–e15.\nZeifman, R.J., Yu, D., Singhal, N., Wang, G., Nayak, S.M., & Weissman, C.R. (2022). Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. The Journal of Clinical Psychiatry, 83(2), 39235.\nNayak, S.M. & Griffiths, R.R. (2022). A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. Frontiers in Psychology, 13, 852248.\nSweeney, M.M., Nayak, S.M., Hurwitz, E.S., Mitchell, L.N., Swift, T.C., & Griffiths, R.R. (2022). Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. PLOS ONE, 17(8), e0271926.\nNayak, S.M., Brigham, J., Gerstenblith, T.A., & Prince, E. (2022). Psychopharmacology in the critical care setting. In K.J. Stucky & J.E. Jutte (Eds.), Critical Care Psychology and Rehabilitation (pp. 235–250). Oxford University Press."
  },
  {
    "objectID": "publications.html#section-4",
    "href": "publications.html#section-4",
    "title": "Publications",
    "section": "2021",
    "text": "2021\nNayak, S.M. & Johnson, M.W. (2021). Psychedelics and psychotherapy. Pharmacopsychiatry, 54(04), 167–175. [pdf]\nNayak, S.M., Gukasyan, N., Barrett, F.S., Erowid, E., Erowid, F., & Griffiths, R.R. (2021). Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: An analysis of online psychedelic experience reports. Pharmacopsychiatry, 54(05), 240–245. [pdf]\nNayak, S.M., Huhn, A.S., Bergeria, C.L., Strain, E.C., & Dunn, K.E. (2021). Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. Drug and Alcohol Dependence, 221, 108649.\nYaden, D.B., Johnson, M.W., Griffiths, R.R., Doss, M., Garcia-Romeu, A., Nayak, S.M., Gukasyan, N., Mathur, B.N., & Barrett, F.S. (2021). Psychedelics and consciousness: Distinctions, demarcations, and opportunities. International Journal of Neuropsychopharmacology, 24(8), 615–623.\nYaden, D.B., Nayak, S.M., Gukasyan, N., Anderson, B.T., & Griffiths, R.R. (2021). The potential of psychedelics for end of life and palliative care. Disruptive Psychopharmacology, 169–184."
  },
  {
    "objectID": "updates.html#december-2024",
    "href": "updates.html#december-2024",
    "title": "Updates",
    "section": "December 2024",
    "text": "December 2024"
  }
]